title: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.
authors.forename: Betty
authors.initials: B
authors.lastname: Cheung
authors.forename: Deepti
authors.initials: D
authors.lastname: Radia
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Pantelidis
authors.forename: Ghasem
authors.initials: G
authors.lastname: Yadegarfar
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D053614:Janus Kinase 2; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000235:genetics*; D013927:Thrombosis / Q000235:genetics*
chemical_list: D006454:Hemoglobins; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2